At the end of September, the FDA approved a once-per-day oral medication Vizimpro as a first-line treatment for patients with a rare form of lung cancer. Pfizer Pharmaceuticals will market the drug.
This blog is focused on providing people who have been diagnosed with either a rare cancer or with more than one cancer a place where they can keep up with information, research and discoveries that could impact their lives in the near term.
Rare cancers and multiple cancers have been ignored for too long. Research dollars are far too limited.
Please let us know if you hear of anything new that needs to be shared with our community.
